3 recruiting, 2 enrolling by invitation, 2 unknown, 1 completed. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Recruiting 3, Enrolling by invitation 2, Unknown 2, Completed 1, Withdrawn 1 |
Follow Severe Asthma: new trials by email Literature Review of Severe Asthma trials Research Report on Severe Asthma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fasenra: An Asthma Study Budesonide-albuterol, Benralizumab - Eosinophilic Asthma, Severe Asthma | Phase 4 | Enrolling by invitation | Endeavor Health | 40 | 2026-07-01 | 2026-09-15 |
| Tezepelumab in the Treatment of Emergency Room Asthma in Adults (TERAA) Tezepelumab, Placebo - Severe Asthma | Phase 4 | Recruiting | University of Alberta | 100 | 2026-05-11 | 2026-07-17 |
| Withdrawal of Dupilumab in Severe Asthma Stopping dupilumab - Severe Asthma | Phase 4 | Recruiting | University Hospital, Toulouse | 205 | 2025-12-15 | 2026-10-08 |
| Beyond EOsinophils: proteoMICS to Identify Potential Biomarker of Organ Damage and Response to MEPOLIZUMAB in EGPA Mepolizumab 100 MG Injection [Nucala], Mepolizumab 300 mg - EGPA - Eosinophilic Granulomatosis With Polyangiitis, Severe Asthma | Phase 4 | Enrolling by invitation | Azienda Ospedaliero Universitaria di Cagliari | 90 | 2025-10-17 | 2026-01-15 |
| Predictive Signature of Benralizumab Response Benralizumab Prefilled Syringe - Asthma; Eosinophilic, Severe Asthma | Phase 4 | Recruiting | Nantes University Hospital | 220 | 2021-10-11 | 2024-04-26 |
| Flow Cytometry Analysis of Eosinophils in Severe Asthma Patients. anti IL5 receptor antibodies - Severe Asthma | Phase 4 | Unknown | Scarlata, Simone, M.D. | 80 | 2021-03-18 | 2021-08-12 |
| Benralizumab in the Treatment of Patients With Severe Asthma With ABPA Fasenra, 30 Mg/mL Subcutaneous Solution - ABPA, Severe Asthma | Phase 4 | Withdrawn | Baylor Research Institute | 2019-12-23 | 2022-02-01 | |
| Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma. Randomisation to omalizumab, Randomisation to mepolizumab - Severe Asthma | Phase 4 | Unknown | Cliniques universitaires Saint-Luc- Université Catholique de Louvain | 100 | 2019-05-10 | 2022-10-27 |
| Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder Placebo, Escitalopram - Severe Asthma, Moderate or Severe Major Depressive Disorder | Phase 4 | Completed | University of Texas Southwestern Medical Center | 26 | 2008-03-01 | 2014-02-04 |
Asthma (9) · Pulmonary Eosinophilia (3) · Aspergillosis, Allergic Bronchopulmonary (1) · Churg-Strauss Syndrome (1) · Depression (1) · Depressive Disorder, Major (1) · Lymphoma, Follicular (1)
Bronchial Diseases (9) · Hypersensitivity (9) · Hypersensitivity, Immediate (9) · Immune System Diseases (9) · Lung Diseases (9) · Lung Diseases, Obstructive (9) · Respiratory Hypersensitivity (9) · Respiratory Tract Diseases (9) · Hemic and Lymphatic Diseases (4) · Eosinophilia (3) · Hematologic Diseases (3) · Hypereosinophilic Syndrome (3) · Leukocyte Disorders (3) · Lymphatic Diseases (2) · Lymphoproliferative Disorders (2)
benralizumab (2) · Escitalopram (1) · Injections (1) · mepolizumab (1) · tezepelumab (1)
Azienda Ospedaliero Universitaria di Cagliari (1) · Baylor Research Institute (1) · Cliniques universitaires Saint-Luc- Université Catholique de Louvain (1) · Endeavor Health (1) · Nantes University Hospital (1) · Scarlata, Simone, M.D. (1) · University Hospital, Toulouse (1) · University of Alberta (1) · University of Texas Southwestern Medical Center (1)
United States (3) · France (2) · Italy (2) · Belgium (1) · Canada (1)
Charles Pilette (1) · E. Sherwood Brown, Ph.D, M.D. (1) · Giselle Mosnaim, MD, MS (1) · Irvin Mayers, MD (1) · Yolanda Mageto, MD (1)
PMID 10109801, PMID 15823451, PMID 16226443, PMID 16478839, PMID 21893215, PMID 26337607, PMID 28500390, PMID 30185520, PMID 31613151, PMID 32729038, PMID 33027187, PMID 34779751, PMID 37914234, PMID 37952772
2017 (1)